Compare TGNA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGNA | ARQT |
|---|---|---|
| Founded | 1906 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.3B |
| IPO Year | N/A | 2020 |
| Metric | TGNA | ARQT |
|---|---|---|
| Price | $19.54 | $27.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $20.00 | ★ $24.83 |
| AVG Volume (30 Days) | 1.7M | ★ 2.0M |
| Earning Date | 11-10-2025 | 10-28-2025 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $2,876,414,000.00 | $317,929,000.00 |
| Revenue This Year | N/A | $85.51 |
| Revenue Next Year | $11.10 | $30.74 |
| P/E Ratio | $9.30 | ★ N/A |
| Revenue Growth | N/A | ★ 129.21 |
| 52 Week Low | $14.87 | $11.13 |
| 52 Week High | $21.35 | $31.77 |
| Indicator | TGNA | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 47.41 |
| Support Level | $19.58 | $28.30 |
| Resistance Level | $19.80 | $31.77 |
| Average True Range (ATR) | 0.19 | 1.14 |
| MACD | 0.03 | -0.57 |
| Stochastic Oscillator | 65.28 | 5.80 |
Tegna Inc is a media company with a portfolio of broadcast stations and digital sites. The firm has television stations and radio stations in approximately U.S. markets. The company owns multicast networks of True Crime Network, Twist, and Quest. Each television station also has a robust digital presence across online, mobile, connected television, and social platforms, reaching consumers on all devices and platforms used to consume news content. It generates key revenue from advertising and marketing services, subscriptions, political advertising, and other services.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.